AH-Chew II

Name: AH-Chew II

What should I discuss with my healthcare provider before taking AH-Chew II (chlorpheniramine, methscopolamine, and phenylephrine)?

You should not use this medication if you are allergic to chlorpheniramine, methscopolamine, or phenylephrine.

Do not use this medicine if you have taken an MAO inhibitor in the past 14 days. A dangerous drug interaction could occur. MAO inhibitors include isocarboxazid, linezolid, phenelzine, rasagiline, selegiline, and tranylcypromine.

Ask a doctor or pharmacist if it is safe for you to take this medicine if you have:

  • asthma or COPD, cough with mucus, or cough caused by smoking, emphysema, or chronic bronchitis;

  • a blockage in your stomach or intestines;

  • kidney or liver disease;

  • high blood pressure, heart disease, coronary artery disease;

  • enlarged prostate or urination problems;

  • glaucoma;

  • pheochromocytoma (an adrenal gland tumor);

  • overactive thyroid; or

  • if you take potassium (Cytra, Epiklor, K-Lyte, K-Phos, Kaon, Klor-Con, Polycitra, Urocit-K).

FDA pregnancy category C. It is not known whether this medicine will harm an unborn baby. Do not use without medical advice if you are pregnant.

This medicine may pass into breast milk and may harm a nursing baby. Antihistamines and decongestants may also slow breast milk production. Do not use without medical advice if you are breast-feeding a baby.

Artificially sweetened cold medicine may contain phenylalanine. If you have phenylketonuria (PKU), check the medication label to see if the product contains phenylalanine.

AH-Chew II (chlorpheniramine, methscopolamine, and phenylephrine) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using this medicine and call your doctor at once if you have:

  • little or no urinating;

  • fast, pounding, or irregular heartbeats;

  • pale skin, weakness, feeling short of breath; or

  • tremors, hallucinations, severe anxiety.

Common side effects may include:

  • blurred vision, headache, dizziness;

  • dry mouth, nose, or throat;

  • nausea; or

  • feeling nervous or restless.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Usual Adult Dose for Nasal Congestion

Tablets:
chlorpheniramine/methscopolamine/PE 8 mg-1.25 mg-20 mg, extended release or
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-25 mg, extended release or
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-40 mg, extended release or
chlorpheniramine/methscopolamine/PE 12 mg-2.5 mg-20 mg extended release or
chlorpheniramine/methscopolamine/PE 12 mg-2 mg-40 mg, extended release or
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-20 mg oral tablet, extended release:
1 tablet orally twice a day, not to exceed 2 doses per day.

chlorpheniramine/methscopolamine/PE 4 mg-1.25 mg-10 mg oral tablet or chlorpheniramine/methscopolamine/PE 2 mg-1.25 mg-10 mg oral tablet, chewable: 1 to 2 tablets orally every 12 hours, not to exceed 4 tablets per day.

chlorpheniramine/methscopolamine/PE varying strength oral tablet, extended release:
chlorpheniramine/methscopolamine/PE 2.5 mg-40 mg extended release: 1 tablet orally in the morning and
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-10 mg extended release: 1 tablet orally in the evening.

chlorpheniramine/methscopolamine/PE ages 6 years and older oral tablet, extended release
chlorpheniramine/methscopolamine/PE 2 mg-1.5 mg-10 mg extended release: 1 or 2 tablets orally in the morning and
chlorpheniramine/methscopolamine/PE 2 mg--1.5 mg extended release: 1 or 2 tablets orally in the evening.

Liquid:
chlorpheniramine/methscopolamine/PE 2 mg-1.5 mg-10 mg/5 mL extended release: 5 to 10 mL orally every 12 hours daily.
chlorpheniramine/methscopolamine/PE 2 mg-0.625 mg-10 mg/5 mL oral syrup 10 mL orally every 4-6 hours, not to exceed 4 doses per day.
chlorpheniramine/methscopolamine/PE 2 mg-1.25 mg-10 mg/5 mL oral syrup: 5 to 10 mL orally every 3-4 hours.
chlorpheniramine/methscopolamine/PE 2 mg-0.75 mg-8 mg/5 mL: 10 mL orally every 4 to 6 hours daily not to exceed 4 doses in 24 hours.
chlorpheniramine/methscopolamine/PE 2 mg-0.75 mg-10 mg/5 mL: 10 mL orally every 4 to 6 hours daily not to exceed 4 doses in 24 hours.
chlorpheniramine/methscopolamine/PE 4 mg-1.25 mg-10 mg/5 mL: 5 to 10 mL orally every 3 or 4 hours daily.

Usual Adult Dose for Rhinitis

Tablets:
chlorpheniramine/methscopolamine/PE 8 mg-1.25 mg-20 mg, extended release or
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-25 mg, extended release or
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-40 mg, extended release or
chlorpheniramine/methscopolamine/PE 12 mg-2.5 mg-20 mg extended release or
chlorpheniramine/methscopolamine/PE 12 mg-2 mg-40 mg, extended release or
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-20 mg oral tablet, extended release:
1 tablet orally twice a day, not to exceed 2 doses per day.

chlorpheniramine/methscopolamine/PE 4 mg-1.25 mg-10 mg oral tablet or chlorpheniramine/methscopolamine/PE 2 mg-1.25 mg-10 mg oral tablet, chewable: 1 to 2 tablets orally every 12 hours, not to exceed 4 tablets per day.

chlorpheniramine/methscopolamine/PE varying strength oral tablet, extended release:
chlorpheniramine/methscopolamine/PE 2.5 mg-40 mg extended release: 1 tablet orally in the morning and
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-10 mg extended release: 1 tablet orally in the evening.

chlorpheniramine/methscopolamine/PE ages 6 years and older oral tablet, extended release
chlorpheniramine/methscopolamine/PE 2 mg-1.5 mg-10 mg extended release: 1 or 2 tablets orally in the morning and
chlorpheniramine/methscopolamine/PE 2 mg--1.5 mg extended release: 1 or 2 tablets orally in the evening.

Liquid:
chlorpheniramine/methscopolamine/PE 2 mg-1.5 mg-10 mg/5 mL extended release: 5 to 10 mL orally every 12 hours daily.
chlorpheniramine/methscopolamine/PE 2 mg-0.625 mg-10 mg/5 mL oral syrup 10 mL orally every 4-6 hours, not to exceed 4 doses per day.
chlorpheniramine/methscopolamine/PE 2 mg-1.25 mg-10 mg/5 mL oral syrup: 5 to 10 mL orally every 3-4 hours.
chlorpheniramine/methscopolamine/PE 2 mg-0.75 mg-8 mg/5 mL: 10 mL orally every 4 to 6 hours daily not to exceed 4 doses in 24 hours.
chlorpheniramine/methscopolamine/PE 2 mg-0.75 mg-10 mg/5 mL: 10 mL orally every 4 to 6 hours daily not to exceed 4 doses in 24 hours.
chlorpheniramine/methscopolamine/PE 4 mg-1.25 mg-10 mg/5 mL: 5 to 10 mL orally every 3 or 4 hours daily.

Usual Pediatric Dose for Rhinitis

12 yrs and older:
Tablets:
chlorpheniramine/methscopolamine/PE 8 mg-1.25 mg-20 mg, extended release or
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-25 mg, extended release or
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-40 mg, extended release or
chlorpheniramine/methscopolamine/PE 12 mg-2.5 mg-20 mg extended release or
chlorpheniramine/methscopolamine/PE 12 mg-2 mg-40 mg, extended release or
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-20 mg oral tablet, extended release:
1 tablet orally twice a day, not to exceed 2 doses per day.

chlorpheniramine/methscopolamine/PE 4 mg-1.25 mg-10 mg oral tablet or chlorpheniramine/methscopolamine/PE 2 mg-1.25 mg-10 mg oral tablet, chewable: 1 to 2 tablets orally every 12 hours, not to exceed 4 tablets per day.

chlorpheniramine/methscopolamine/PE varying strength oral tablet, extended release:
chlorpheniramine/methscopolamine/PE 2.5 mg-40 mg extended release: 1 tablet orally in the morning and
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-10 mg extended release: 1 tablet orally in the evening.

chlorpheniramine/methscopolamine/PE ages 6 years and older oral tablet, extended release
chlorpheniramine/methscopolamine/PE 2 mg-1.5 mg-10 mg extended release: 1 or 2 tablets orally in the morning and
chlorpheniramine/methscopolamine/PE 2 mg--1.5 mg extended release: 1 or 2 tablets orally in the evening.

Liquid:
chlorpheniramine/methscopolamine/PE 2 mg-1.5 mg-10 mg/5 mL extended release: 5 to 10 mL orally every 12 hours daily.
chlorpheniramine/methscopolamine/PE 2 mg-0.625 mg-10 mg/5 mL oral syrup 10 mL orally every 4-6 hours, not to exceed 4 doses per day.
chlorpheniramine/methscopolamine/PE 2 mg-1.25 mg-10 mg/5 mL oral syrup: 5 to 10 mL orally every 3-4 hours.
chlorpheniramine/methscopolamine/PE 2 mg-0.75 mg-8 mg/5 mL: 10 mL orally every 4 to 6 hours daily not to exceed 4 doses in 24 hours.
chlorpheniramine/methscopolamine/PE 2 mg-0.75 mg-10 mg/5 mL: 10 mL orally every 4 to 6 hours daily not to exceed 4 doses in 24 hours.
chlorpheniramine/methscopolamine/PE 4 mg-1.25 mg-10 mg/5 mL: 5 to 10 mL orally every 3 or 4 hours daily.

6 yrs to 11 yrs:
Liquid:
chlorpheniramine/methscopolamine/PE 4 mg-1.25 mg-10 mg/5 mL: 2.5 to 5 mL orally every 4 hours daily.
chlorpheniramine/methscopolamine/PE 2 mg-0.75 mg-8 mg/5 mL: 5 mL orally every 4 to 6 hours daily not to exceed 4 doses in 24 hours.
chlorpheniramine/methscopolamine/PE 2 mg-0.75 mg-10 mg/5 mL: 5 mL orally every 4 to 6 hours daily not to exceed 4 doses in 24 hours.

chlorpheniramine/methscopolamine/PE 2 mg-1.5 mg-10 mg/5 mL, extended release 2.5 to 5 mL orally every 12 hours daily.

Chew tab:
chlorpheniramine/methscopolamine/PE 2 mg-1.25 mg-15 mg chewable: 1 tablet orally every 4 hours not to exceed 4 tablets per day.

Tablets:
chlorpheniramine/methscopolamine/PE 8 mg-1.25 mg-20 mg, extended release or
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-25 mg, extended release or
chlorpheniramine/methscopolamine/PE 8 mg-2.5 mg-40 mg, extended release or
chlorpheniramine/methscopolamine/PE 12 mg-2.5 mg-20 mg, extended release or
chlorpheniramine/methscopolamine/PE 12 mg-2 mg-40 mg, extended release:
1/2 tablet orally twice daily, not to exceed 2 doses per day.

chlorpheniramine/methscopolamine/PE 2 mg-1.25 mg-10 mg oral tablet, chewable: 1/2 to 1 tablet orally every 12 hours, not to exceed 2 tablets per day.

chlorpheniramine/methscopolamine/PE ages 6 years and older oral tablet, extended release
chlorpheniramine/methscopolamine/PE 2 mg-1.5 mg-10 mg extended release: 1/2 to 1 tablet orally in the morning and
chlorpheniramine/methscopolamine/PE 2 mg--1.5 mg extended release: 1/2 to 1 tablet orally in the evening.

Chlorpheniramine / methscopolamine / phenylephrine Breastfeeding Warnings

Small amounts of sympathomimetic amines and antihistamines are excreted in breast milk and because of the risk of adverse reactions in nursing infants (excitement or irritability), use is not recommended. Anticholinergics and antihistamines may inhibit lactation.

(web3)